Precision Therapeutics, Inc. Release: Two Pivotal Manuscripts On ChemoFx Accepted For Publication
6/26/2014 11:05:57 AM
PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics, Inc. announces that two key manuscripts on the ChemoFx® drug response marker have been accepted for publication. British Journal of Cancer, the elite professional medical journal of Cancer Research UK, has accepted a manuscript detailing the predictive abilities of ChemoFx. In addition, Clinical and Translational Oncology has accepted a manuscript that examines whether access to ChemoFx results has a positive impact on patient outcomes. Together, these key publications will provide further evidence of the clinical utility of the drug response marker as well as answer important clinical questions asked by physicians personalizing patient treatment and payers covering this important test.
Help employers find you! Check out all the jobs and post your resume.
comments powered by